WHO Pharmaceuticals Newsletter 1998, No. 03&04
(1998; 18 pages)
Índice de contenido
Cerrar esta carpetaRegulatory actions
Ver el documentoAluminium in total parenteral nutrition - labelling requirements & warning
Ver el documentoAstemizole - warning concerning cardiovascular adverse events
Ver el documentoBromfenac - warning label: liver damage
Ver el documentoCarbamazepine - warning concerning precipitation
Ver el documentoChlormezanone - withdrawn
Ver el documentoCounterfeit drugs - warning to the public
Ver el documentoDietary supplement "Sleeping Buddha" - warning concerning estazolam content
Ver el documentoFenfluramine - withdrawn
Ver el documentoHuman dura mater (freeze-dried) - restrictive measures
Ver el documentoIsotretinoin - psychiatric adverse effects
Ver el documentoPyrithione zinc (Skin-CapR) - withdrawn
Ver el documentoSertindole - approval application withdrawn
Ver el documentoTerfenadine - additional drug interactions
Ver el documentoTerfenadine - withdrawn following approval of fexofenadine
Abrir esta carpeta y ver su contenidoDrug surveillance
Abrir esta carpeta y ver su contenidoNew developments
Ver el documentoRecent approvals
Abrir esta carpeta y ver su contenidoMedical devices
Abrir esta carpeta y ver su contenidoGeneral information
Abrir esta carpeta y ver su contenidoVeterinary medicine
 

Terfenadine - additional drug interactions

United Kingdom. The Committee on Safety of Medicines has identified several agents that interact with terfenadine: imidazole antifungals, macrolide antibiotics and grapefruit juice. Accumulation of terfenadine can cause cardiac arrhythmias when its hepatic metabolism is reduced by disease or by agents that interact with the relevant enzymes. Similar interactions have been found to occur with the following drugs and the Committee therefore recommends that they should not be used with terfenadine:

• mibefradil (PosicorR)
• serotonin reuptake inhibitors (fluvoxamine, nefazodone, sertraline)
• HIV protease inhibitors (indinavir, ritonavir, squinavir).
• cisapride.

[See also Pharmaceuticals Newsletter Nos. 9&10, September&October and Nos. 3&4, March&April 1997]

Reference: Current Problems in Pharmacovigilance Vol. 23, December 1997.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013